Therion Biologics
Executive Summary
Cambridge, Mass.-based development-stage company completes $4.1 mil. private placement. Funds will be used to advance development of the firm's cancer immunotherapeutic and for preclinical studies in AIDS. Phase I/II trials of Therion's lead cancer product, the live recombinant vaccine TBC-CEA (carcinoembryonic antigen), have begun with the National Cancer Institute for colorectal, breast and lung cancers.